

Development of first-in-class endoglin-targeted CAR-NK and its application for inducing immune-friendly microenvironment

Korea Institute of Science and Technology (KIST)



ONCOLOGY	Lead
Product Type	CAR-NK cells
Indication	Solid cancer
Target	Endoglin (CD105)
MoA(Mechanism of Action)	Engineered CAR-NK-mediated cytotoxicity against endoglin-expressing CAFs as well as cancer cells
Competitiveness	“First-in-class” CAR-NK immunotherapy against solid cancers including pancreatic and colon cancers, which target endoglin strongly expressed in cancer-associated fibroblasts
Development Stage	Lead
Route of Administration	I.V or I.P injection